Nevro (NYSE:NVRO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Nevro (NYSE:NVRO) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the stock. JMP Securities restated a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Wells Fargo & Company decreased their price objective on shares of Nevro from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Robert W. Baird lifted their target price on Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. Morgan Stanley downgraded Nevro from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $9.00 to $4.00 in a report on Monday, December 2nd. Finally, Jefferies Financial Group upgraded Nevro from an “underperform” rating to a “hold” rating and raised their price target for the stock from $4.50 to $5.85 in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $6.43.

Nevro Trading Up 0.1 %

Shares of NYSE:NVRO opened at $5.74 on Wednesday. Nevro has a 52 week low of $3.16 and a 52 week high of $15.98. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $214.90 million, a PE ratio of -3.03 and a beta of 0.91. The company’s 50 day moving average is $4.70 and its two-hundred day moving average is $4.93.

Institutional Investors Weigh In On Nevro

Several large investors have recently modified their holdings of NVRO. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Nevro by 130.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock valued at $5,590,000 after buying an additional 566,462 shares during the last quarter. Western Standard LLC purchased a new stake in shares of Nevro in the third quarter valued at about $5,473,000. Charles Schwab Investment Management Inc. increased its stake in shares of Nevro by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 303,675 shares of the medical equipment provider’s stock worth $1,698,000 after acquiring an additional 11,369 shares during the period. Engaged Capital LLC raised its holdings in Nevro by 29.5% during the third quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock worth $13,656,000 after purchasing an additional 557,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Nevro by 27.6% in the third quarter. Assenagon Asset Management S.A. now owns 929,348 shares of the medical equipment provider’s stock valued at $5,195,000 after purchasing an additional 200,885 shares during the period. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.